LY-2228820-d9
p38MAPK抑制剂内标物；
LY-2228820-d9
p38MAPK抑制剂内标物；
LY-2228820-d9
-
产品编号： CLR486502
-
相关CAS号：862507-23-1（未标记）
-
分子式：C26H28D9FN6O6S2
-
分子量：621.79
-
EINECES：208-889-9
英文别名：
5-[2-(1,1-Dimethylethyl)-5-(4-fluorophenyl)-1H-imidazol-4-yl]-3-(2,2-dimethylpropyl)-3H-imidazo[4,5-b]pyridin-2-amine-d9 Dimethanesulfonate
SMILES：
CC([C@@H]1CC[C@@]2(C)[C@H]1C1CC[C@@H]3[C@]4(CC[C@H](O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2)C)=C
参考文献：
Zhao, R. et al.: Drug Metab. Disp., 37, 1251 (2009); Ishitsuka, K. et al.: Br. J. Haematol., 141, 598 (2008); Mader, M. et al.: Bioorg. Med. Chem. Lett., 18, 179 (2008);
Laballed LY2228820, a novel and potent p38MAPK inhibitor with potent antiinflammatory activity. LY2228820 significantly inhibited phosphorylation of MAPKAPK2 and/or HSP27, down stream targets of p38MAPK, in both multiple myeloma (MM) cell lines and LT-BMSCs. LY2228820 is a potential candidate to improve MM patient outcome both by enhancing the effect of Bortezomib (B675700) and by reducing osteoskeletal events.
搜索质检报告(COA)
搜索MSDS
